Articles tagged "Kidney transplantation"

2018 American Transplant Congress
T-Cell Depletion Does Not Increase the Risk of CMV Infection in Donor-Positive, Recipient-Negative Kidney Transplants Due to the Absence of Preformed CMV-Specific Cell-Mediated Immunity
M. Jarque,¹ H. Kaminski,² L. Couzi,² E. Crespo,¹ J. Déchanet-Merville,³ S. Luque,¹ N. Montero,⁴ M. Pascual,⁵ O. Manuel,^5,6 P. Merville,² O. Bestard.^1,4
¹Nephrology Lab, IDIBELL, Barcelona, Spain; ²Nephrology Dep, Hôpital Pellegrin, Bordeaux, France; ³National Center of Scientific Research, Bordeaux, France; ⁴Nephrology Dep, Bellvitge Hospital, Barcelona, Spain; ⁵Transplantation Center, Lausanne Hospital, Lausanne, Switzerland; ⁶Infectious Diseases Dep, Lausanne Hospital, Lausanne, Switzerland.
Kidney transplants (KT) with R-/D+ CMV serostatus receiving T-cell depletion induction are considered as the highest risk population for CMV infection and long-lasting prophylaxis therapy…
2018 American Transplant Congress
Prospective, Double Blind, Randomized Trial Comparing the Use of Ketorolac and Lyrica versus SOC+placebo during Live Donor Nephrectomy for Transplant
J. Campsen,¹ T. Call,² A. Rosales,¹ C. Allen,³ A. Presson,³ R. Kim.¹
¹Trasplantation and Advanced Hepatobiliary Surgery, University of Utah, Salt Lake City, UT; ²Anesthesiology, University of Utah, Salt Lake City, UT; ³Epidemiology, University of Utah, Salt Lake City, UT.
Opioid exposure is a concern after live donation (LD) for transplant. We theorized that a protocol using pregablin pre-operation to desensitize nerves followed by ketorolac…
2018 American Transplant Congress
RNA-Seq Based Analysis of Renal Allograft Biopsies Reveals Key Mediators of Interstitial Fibrosis/Tubular Atrophy
C. McEvoy,^1,2,4 E. Brennan,^1,2 A. Dorman,^2,3 D. Sadlier,^1,2 A. Konvalinka,⁴ P. Conlon,^2,3 C. Godson.^1,2
¹Diabetes Complications Research Centre, Conway Institute, School of Medicine, University College Dublin, Dublin, Ireland; ²North Dublin Renal Biobank, Dublin, Ireland; ³Beaumont Hospital & RCSI, Dublin, Ireland; ⁴University Health Network, Toronto, Canada.
Interstitial Fibrosis/Tubular Atrophy(IFTA) is the final common pathway of most progressive renal diseases and is a potent predictors of renal outcome in both native and…
2018 American Transplant Congress
Programmed Cell Death Ligand 1 (PD-L1) Expression is Associated with Subtypes of Post-Transplant Lymphoproliferative Disorders (PTLD)
N. Rodig,¹ G. Pinkus,² G. Ramos Gonzalez,³ T. Agur,¹ O. Weinberg.⁴
¹Pediatrics, Boston Children's Hospital, Boston, MA; ²Pathology, Brigham and Women's Hospital, Boston, MA; ³Surgery, Boston Children's Hospital, Boston, MA; ⁴Pathology, Boston Children's Hospital, Boston, MA.
Introduction: PD-L1 expression on select tumor cells engages the PD-1 receptor on T cells, inhibiting anti-tumor immune responses. PD-L1 has been detected in cases of…
2018 American Transplant Congress
modified DFPP Can Eliminate Donor-Reactive IgG Antibody with Preserving Fibrinogen before Kidney Transplantation
D. Iwami,¹ T. Matsumoto,² K. Hotta,¹ M. Ota,² Y. Chiba,² H. Higuchi,¹ N. Shinohara.¹
¹Renal and Genitourinary Surgery, Hokkaido University, Graduate School of Medicine, Sapporo, Hokkaido, Japan; ²Medical Engineering Center, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
BACKGROUND: Elimination of preexisting IgG antibodies against donor antigen is an important role before antibody-incompatible (i.e. ABO-incompatible and donor-specific antibody positive) kidney transplantation. Plasma exchange…
2018 American Transplant Congress
Novel Vascular Inflow Offers Renal Transplantation to Recipients with Severe Central and Peripheral Vascular Disease
S. Mao,¹ E. Giorgakis,² A. Moss,² T. Taner.¹
¹William J. von Liebig Center for Transplantation, Mayo Clinic, Rochester, MN; ²Transplantation Surgery, Mayo Clinic, Phoenix, AZ.
Background: Absence of suitable implant locations for donor renal vessels may be a major problem in patients with significant central and peripheral vascular disease. We…
2018 American Transplant Congress
Impact of KDPI and CPRA on Outcomes in Kidney Transplant Recipients
S. Sethi, R. Najjar, A. Peng, A. Vo, S. Jordan, E. Huang.
Cedars Sinai Medical Center, Los Angeles.
Introduction: The new KAS has led to a marked increase in kidney transplants among highly sensitized recipients, mostly attributable to higher allocation of low KDPI…
2018 American Transplant Congress
Temporal Changes in the Characteristics and Sensitization of Kidney Paired Donation Registrants
C. Holscher,¹ K. Jackson,¹ A. Thomas,¹ C. Haugen,¹ S. DiBrito,¹ M. Ronin,² A. Waterman,^3,4 A. Massie,^1,5 J. Garonzik Wang,¹ D. Segev.^1,5
¹Johns Hopkins School of Medicine, Baltimore; ²National Kidney Registry, New York; ³David Geffen School of Medicine at UCLA, Los Angeles; ⁴Terasaki Research Institute, Los Angeles; ⁵Johns Hopkins School of Public Health, Baltimore.
In order to utilize a willing but incompatible living donor, candidates must either proceed with incompatible transplantation or find a more compatible match using kidney…
2018 American Transplant Congress
Cost Effectiveness of Lifelong Medicare Immunosuppressant Drug Coverage for Kidney Transplant Recipients in the Current Era
M. Kadatz,¹ J. Gill,² J. Gill,² K. Scott.³
¹Clinician Investigator Program, University of British Columbia, Vancouver, BC, Canada; ²Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada; ³Division of Nephrology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
While there is no Medicare time limit for dialysis patients, kidney transplant recipients lose their Medicare coverage 36 months after they receive their transplant. The…
2018 American Transplant Congress
RNA Expression Profiling of Renal Allografts in the Cynomolgus Monkey Identifies Tolerance
R. Smith,¹ M. Matsunami,³ B. Adam,² A. Rosales,¹ T. Oura,³ A. Cosimi,³ T. Kawai,³ M. Mengel,² R. Colvin.¹
¹Pathology, Massachusetts General Hospital, Boston, MA; ²Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; ³Department of Surgery, Massachusetts General Hospital, Boston, MA.
IntroductionTolerance induction is a long standing clinical goal. However, identification remains elusive. Here we profile intra-renal allograft RNA expression in a mixed chimerism renal allograft…